Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease

Neurobiology of Aging

Volumn 34, Issue 3, 2013, Pages 887-901

  Bourque, Mélanie ^a,b   Morissette, Marc ^a   Côté, Mélissa ^c   Soulet, Denis ^c   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

17 estradiol; Dopamine; GPER1; MPTP; Neuroprotection; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; PROTEIN INHIBITOR; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL DENSITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ESTRADIOL; MALE; MICE; MICE, INBRED C57BL; PARKINSONIAN DISORDERS; RECEPTORS, G-PROTEIN-COUPLED; SUBSTANTIA NIGRA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84870506789     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.05.022     Document Type: Article

References (39)

1. Abdelhamid R., Luo J., Vandevrede L., Kundu I., Michalsen B., Litosh V.A., Schiefer I.T., Gherezghiher T., Yao P., Qin Z., Thatcher G.R. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem. Neurosci 2011, 2:256-268.
2. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec 1946, 94:239-247.
3. Al-Sweidi S., Morissette M., Bourque M., Di Paolo T. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Neuropharmacology 2011, 61:583-591.
4. Blanchet P.J., Fang J., Hyland K., Arnold L.A., Mouradian M.M., Chase T.N. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999, 53:91-95.
5. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savchuck N.P., Sklar L.A., Oprea T.I., Prossnitz E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol 2006, 2:207-212.
6. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol 2009, 30:142-157.
7. Callier S., Morissette M., Grandbois M., Pélaprat D., Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001, 41:131-138.
8. D'Astous M., Morissette M., Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 2004, 47:1180-1188.
9. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T.K., Bologa C.G., Leitao A., Brailoiu E., Deliu E., Dun N.J., Sklar L.A., Hathaway H.J., Arterburn J.B., Oprea T.I., Prossnitz E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol 2009, 5:421-427.
10. Di Paolo T., Rouillard C., Bédard P. 17 beta-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur. J. Pharmacol 1985, 117:197-203.
11. Dluzen D.E., McDermott J.L., Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol 1996, 18:603-606.
12. Ekue A., Boulanger J.F., Morissette M., Di Paolo T. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice. J. Neuroendocrinol 2002, 14:731-736.
13. Franklin K., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 1997, Academic Press, San Diego.
14. Gao F., Ma X., Ostmann A.B., Das S.K. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals. Endocrinology 2011, 152:1434-1447.
15. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci 1987, 7:3915-3934.
16. Gingerich S., Kim G.L., Chalmers J.A., Koletar M.M., Wang X., Wang Y., Belsham D.D. Estrogen receptor α and G-protein coupled receptor 30 mediate the neuroprotective effects of 17β-estradiol in novel murine hippocampal cell models. Neuroscience 2010, 170:54-66.
17. Goekoop R., Duschek E.J., Knol D.L., Barkhof F., Netelenbos C., Scheltens P., Rombouts S.A. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. Neuroimage 2005, 25:63-75.
18. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia-normal and in Parkinson's disease. J. Chem. Neuroanat 2001, 22:3-12.
19. Kilbourn M., Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur. J. Pharmacol 1996, 307:227-232.
20. Kitamura N., Araya R., Kudoh M., Kishida H., Kimura T., Murayama M., Takashima A., Sakamaki Y., Hashikawa T., Ito S., Ohtsuki S., Terasaki T., Wess J., Yamada M. Beneficial effects of estrogen in a mouse model of cerebrovascular insufficiency. PLoS One 2009, 4:e5159.
21. Kumar P., Wu Q., Chambliss K.L., Yuhanna I.S., Mumby S.M., Mineo C., Tall G.G., Shaul P.W. Direct interactions with G α i and G βγ mediate nongenomic signaling by estrogen receptor α. Mol. Endocrinol 2007, 21:1370-1380.
22. Lebesgue D., Traub M., De Butte-Smith M., Chen C., Zukin R.S., Kelly M.J., Etgen A.M. Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS One 2010, 5:e8642.
23. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Björklund A., Widner H., Revesz T., Lindvall O., Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
24. Liang C.L., Sinton C.M., Sonsalla P.K., German D.C. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 1996, 5:313-318.
25. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol 2007, 34:555-565.
26. Meyers B., D'Agostino A., Walker J., Kritzer M.F. Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats. Neuroscience 2010, 165:850-862.
27. Mitra S.W., Hoskin E., Yudkovitz J., Pear L., Wilkinson H.A., Hayashi S., Pfaff D.W., Ogawa S., Rohrer S.P., Schaeffer J.M., McEwen B.S., Alves S.E. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003, 144:2055-2067.
28. Morissette M., Jourdain S., Al Sweidi S., Menniti F.S., Ramirez A.D., Di Paolo T. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 2007, 52:1509-1520.
29. Otto C., Fuchs I., Kauselmann G., Kern H., Zevnik B., Andreasen P., Schwarz G., Altmann H., Klewer M., Schoor M., Vonk R., Fritzemeier K.H. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod 2009, 80:34-41.
30. Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., Langer G., Bader B., Prelle K., Nubbemeyer R., Fritzemeier K.H. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008, 149:4846-4856.
31. Pasqualini C., Olivier V., Guibert B., Frain O., Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem 1995, 65:1651-1657.
32. Pedram A., Razandi M., Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol 2006, 20:1996-2009.
33. Prossnitz E.R., Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat 2009, 89:89-97.
34. Prossnitz E.R., Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol 2011, 7:715-726.
35. Saunders-Pullman R., Gordon-Elliott J., Parides M., Fahn S., Saunders H.R., Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999, 52:1417-1421.
36. Shulman L.M. Gender differences in Parkinson's disease. Gend. Med 2007, 4:8-18.
37. Singh M., Sétáló G., Guan X., Warren M., Toran-Allerand C.D. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J. Neurosci 1999, 19:1179-1188.
38. Taylor H.S., Manson J.E. Update in hormone therapy use in menopause. J. Clin. Endocrinol. Metab 2011, 96:255-264.
39. Ullrich N.D., Krust A., Collins P., MacLeod K.T. Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol 2008, 294:H2421-H2427.